Crescent Biopharma, Inc.

CBIO
$16.76 (- $0.05 - 0.30%)
Last updated: 2026-07-10 12:43 UTC
CBIO Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINKYG2545C1042
Market Price16.76
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyQuarterly
P/E RatioN/A
EPSN/A
Market Cap$203.4M
Book Value5.76
Price to Book2.103
BetaN/A
52w High37.0
52w Low9.81
Next Earnings DateN/A

Crescent Biopharma, Inc. trades under ticker CBIO on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN KYG2545C1042.

About the Company
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Price History